Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Sep 05, 2018 10:34am

96 Views

Post# 28565064

RE:Kwang Dong

This suggests otherwise

https://koreabizwire.com/yuhan-gc-pharma-kwang-dong-top-pharmaceutical-industry/111724

CyrolQue wrote:
With a market cap of about 360mln US$, it represents a meagre 0.5% of the SKorean pharmas (those in the KOSPI index anyway).

So, I wouldn’t exactly refer to them as a ‘major’ pharmaceutical in the region as the press release states.

So, not mind blowing and, definitely, not a game changer but positive news anyway.